ABHH
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular

Discussão Guia ESMO Mieloma 2021

Angelo Maiolino , Edvan Crusoe, Vania Hungria

ABHH®
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular

Conflitos de interesse

Honorário **Sanofi**

ABHH
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular

2017

ESMO GOOD SCIENCE BETTER MEDICINE BEST PRACTICE

Annals of Oncology 0: 1–11, 2017
doi:10.1093/annonc/mdx096

CLINICAL PRACTICE GUIDELINES

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

P. Moreau[1], J. San Miguel[2], P. Sonneveld[3], M. V. Mateos[4], E. Zamagni[5], H. Avet-Loiseau[6], R. Hajek[7], M. A. Dimopoulos[8], H. Ludwig[9], H. Einsele[10], S. Zweegman[11], T. Facon[12], M. Cavo[5], E. Terpos[8], H. Goldschmidt[13], M. Attal[6] & C. Buske[14], on behalf of the ESMO Guidelines Committee*

2020

HemaSphere
Powered by EHA

EHA EUROPEAN HEMATOLOGY ASSOCIATION

Guideline Article - Consensus based

OPEN ACCESS

Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up

Meletios A. Dimopoulos[1], Philippe Moreau[2], Evangelos Terpos[1], María-Victoria Mateos[3], Sonja Zweegman[4], Gordon Cook[5], Michel Delforge[6], Roman Hájek[7], Fredrik Schjesvold[8,9], Michele Cavo[10], Hartmut Goldschmidt[11], Thierry Facon[12], Hermann Einsele[13], Mario Boccadoro[14], Jesús San-Miguel[15], Pieter Sonneveld[16], Ulrich Mey[17], on behalf of the EHA Guidelines Committee and the ESMO Guidelines Committee

Smouldering Myeloma

2017

Immediate treatment is not recommended at the present time for patients with indolent myeloma.
Clinical trials for high-risk smouldering myeloma are strongly encouraged.

2020

	Proposed cut-off	Analysis	HR (95% CI) versus low risk	*P* value
Serum M protein	2 g/dl	>2 versus ≤2	1.99 (1.62-2.45)	<0.0001
Serum FLC ratio	20	>20 versus ≤20	2.04 (1.65-2.52)	<0.0001
BMPC %	20%	>20 versus ≤20	2.26 (1.83-2.79)	<0.0001

median time to progression

low- 110 m
intermediate- 68 m
high-risk 29 months,

($P < 0.0001$).

High-risk SMM patients should be encouraged to participate in randomised phase III trials to reveal the best treatment that offers OS advantage. To date, no treatment has been approved for SMM.

Eligible Myeloma

2017



2020



Non- eligible Myeloma

2017





2020

1st Relapse Myeloma



2017



2020



2nd or more Relapses Myeloma



And Beyond……

Anti BCMA	**Anti- G protein-coupled receptor family C group 5-member D (GPRC5D)**	**Fc receptor-homolog 5 (FcRH5)**

1- CART

2- BiTE

3- ConjMoAb